¼¼°èÀÇ ÁöÁÖ¸·³¶Á¾ Ä¡·á ½ÃÀå
Arachnoid Cysts Treatment
»óǰÄÚµå : 1773978
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 462 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,228,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,684,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁöÁÖ¸·³¶Á¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 17¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÁöÁÖ¸·³¶Á¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 17¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 3.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ µÎ°³³» ÁöÁÖ¸·³¶Á¾Àº CAGR 3.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ô¼ö ÁöÁÖ¸·³¶Á¾ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 6,320¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁöÁÖ¸·³¶Á¾ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 3¾ï 6,320¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.9%¸¦ ±â·ÏÇϸç 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 3¾ï 3,380¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.6%¿Í 2.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁöÁÖ¸·³¶Á¾ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÁöÁÖ¸·³¶Á¾À̶õ ¹«¾ùÀΰ¡?

ÁöÁÖ¸·³¶Á¾Àº ³ú¿Í ô¼ö¿Í ÁßÃ߽Űæ°è¸¦ µÑ·¯½Î°í ÀÖ´Â ¼¼ °³ÀÇ º¸È£¸· Áß ÇϳªÀÎ °Å¹Ì¸· »çÀÌ¿¡ ¹ß»ýÇÏ´Â ¾×ü·Î ä¿öÁø ³¶Á¾ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³¶Á¾Àº ¼±ÃµÀûÀÎ °æ¿ì°¡ ¸¹Áö¸¸, ¿Ü»óÀ̳ª °¨¿°, ³ú¼ö¼úÀÇ ÇÕº´ÁõÀ¸·Î ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù. ´ëºÎºÐÀÇ ÁöÁÖ¸·³¶Á¾Àº ¹«Áõ»óÀÎ °æ¿ì°¡ ¸¹¾Æ ¿µ»ó °Ë»ç¿¡¼­ ¿ì¿¬È÷ ¹ß°ßµÇÁö¸¸, Áõ»óÀÌ ÀÖ´Â °æ¿ì µÎÅë, ¾îÁö·³Áõ, °æ·Ã, ¼öµÎÁõ, ÀÎÁöÀå¾Ö µîÀÇ ½Å°æÇÐÀû ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚ±â°ø¸í¿µ»ó¹ý(MRI), ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CT), ³úô¼ö¾× È帧°Ë»ç µî ¿µ»ó Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ³úô¼ö³¶Á¾ÀÇ ¹ß°ß°ú Ư¡ÀÌ Å©°Ô °³¼±µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, °íÇØ»óµµ ¿µ»ó Áø´Ü µµ±¸ÀÇ »ç¿ëÀ¸·Î Á¶±â Áø´Ü ¹× Ä¡·á °èȹÀÌ °¡´ÉÇØÁ® Àå±âÀûÀÎ ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀΰøÁö´É(AI) ±â¹Ý ¹æ»ç¼± Áø´Ü ¼Ö·ç¼ÇÀº ³¶Á¾ ºÐ·ùÀÇ Á¤È®µµ¸¦ Çâ»ó½ÃÄÑ Áõ»ó¼º ³¶Á¾°ú ¿ì¹ß¼º ³¶Á¾À» ±¸ºÐÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÇ·áÁøÀÌ Áø´Ü ÇÁ·ÎÅäÄÝÀ» Áö¼ÓÀûÀ¸·Î °³¼±ÇÔ¿¡ µû¶ó, ³úÇϼöü ³¶Á¾ °ü¸®¿¡¼­ Ä¡·á °áÁ¤À» ¾È³»ÇÏ´Â Á¤¹Ð ¿µ»óÀÇ ¿ªÇÒÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

ÁöÁÖ¸·³¶Á¾ Ä¡·áÀÇ ¼ö¼úÀû, ºñ¼ö¼úÀû Á¢±Ù¹ýÀº ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

³úÇϼöü ³¶Á¾ÀÇ Ä¡·á´Â Áõ»óÀÇ ½É°¢¼º, ³¶Á¾ÀÇ Å©±â, ºÎÀ§¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ¹«Áõ»ó ³¶Á¾Àº ´ëºÎºÐ Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾ÊÁö¸¸, Áõ»óÀÌ ÀÖ´Â °æ¿ì¿¡´Â ºñ¼ö¼úÀû °ü¸® ¶Ç´Â ¼ö¼úÀû Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. °æÁõÀÇ °æ¿ì ÁøÅëÁ¦, Ç×°æ·ÃÁ¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å¿Í °°Àº ¾à¸®ÇÐÀû Ä¡·á·Î Áõ»óÀ» Á¶ÀýÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÁøÇ༺ ½Å°æÀå¾Ö, ¼öµÎÁõ, µÎ°³³»¾ÐÇ×ÁøÁõÀÌ Àִ ȯÀÚ¿¡°Ô´Â ¼ö¼úÀû Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ½Å°æ¿Ü°ú ±â¼úÀÇ ¹ßÀüÀº ÁöÁÖ¸·³¶Á¾ Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ³»½Ã°æÀû °ÝÀÚÇü ÀýÁ¦¼ú, ¹æ±¤º¹°­ ¼ÇÆ®¼ú, ¹Ì¼¼¼ö¼úÀû ÀýÁ¦¼ú µîÀÇ ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÌ °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ƯÈ÷, ³»½Ã°æÀû ¹æ±¤¿ä°üÀýÁ¦¼úÀº ÇÕº´Áõ À§Çè °¨¼Ò, ȸº¹ ½Ã°£ ´ÜÃà, ¼ö¼ú ÈÄ ¿¹ÈÄ °³¼±À¸·Î ÀÎÇØ ¼±È£µÇ´Â ¼ö¼ú¹ýÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú Áß ½Å°æ Ž»ö°ú ½Ç½Ã°£ À̹ÌÁöÀÇ ÅëÇÕÀ¸·Î ¼ö¼ú Á¤È®µµ°¡ Çâ»óµÇ°í ÁÖº¯ ³ú ±¸Á¶¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ·Îº¿ º¸Á¶ ³ú¼ö¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÊ¿¡ µû¶ó ¼ÕÀçÁÖ, ¼ö¼ú ½Ã°£ ´ÜÃà, ȯÀÚ ¾ÈÀü¼ºÀÌ Çâ»óµÇ¾î Ä¡·á ¹æ¹ýÀÌ ´õ¿í º¯È­Çϰí ÀÖ½À´Ï´Ù. ¼ö¼úÀÇ Çõ½ÅÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ½Å°æ¿Ü°ú ÀÇ»çµéÀº ÁöÁÖ¸·³¶Á¾ ȯÀÚÀÇ °á°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇØ °³º°È­µÈ Á¢±Ù¹ýÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù.

ÁöÁÖ¸·³¶Á¾ Ä¡·á ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½ÃÀå µ¿ÇâÀº ¹«¾ùÀΰ¡?

½Å°æÁúȯ ¹ß»ý·ü Áõ°¡, ½Å°æ¿Ü°ú ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Á¤¹ÐÀÇ·áÀÇ ¹ßÀü µî ¿©·¯ ½ÃÀå µ¿ÇâÀÌ ÁöÁÖ¸·³¶Á¾ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. °£Áú, ¼öµÎÁõ, ¿Ü»ó¼º ³ú¼Õ»ó µî ½Å°æ ÁúȯÀÇ ¼¼°èÀû À¯ÇàÀ¸·Î ÀÎÇØ ÁöÁÖ¸·³¶Á¾¿¡ ´ëÇÑ Á¶±â °³ÀÔ°ú ÷´Ü Ä¡·á Àü·«¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æ°ú ¹× ½Å°æ¿Ü°ú Àü¹® ¼¾ÅÍÀÇ È®ÀåÀ¸·Î ¾çÁúÀÇ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î ´õ ¸¹Àº ȯÀÚµéÀÌ ÃÖ÷´Ü Ä¡·á¹ýÀÇ ÇýÅÃÀ» ´©¸± ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Á᫐ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ºñħ½ÀÀû, ÃÖ¼Òħ½ÀÀû Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Çõ½ÅÀûÀÎ ¼ö¼ú µµ±¸¿Í ½Å°æ ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æ¿Ü°ú ¼ö¼ú °èȹ¿¡ AI¿Í ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© ¿¹Ãø ºÐ¼®°ú ½Ç½Ã°£ ÀÇ»ç°áÁ¤À» °¡´ÉÇϰÔÇÔÀ¸·Î½á Ä¡·á °á°ú¸¦ ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. ½Å°æÇÐÀû °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇ·á ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó, ³úô¼ö³¶Á¾ Ä¡·á ȯ°æÀº ȯÀÚ¿Í ÀÇ·áÁøÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

ÁöÁÖ¸·³¶Á¾ Ä¡·á ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÁöÁÖ¸·³¶Á¾ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ½Å°æ¿Ü°ú ¼ö¼úÀÇ ±â¼ú ¹ßÀü, AI¸¦ Ȱ¿ëÇÑ Áø´Ü ¹æ¹ýÀÇ Ã¤Åà Áõ°¡, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ³»½Ã°æ ¹× ·Îº¿ º¸Á¶ ½Å°æ¿Ü°ú ¼ö¼úÀÇ Áö¼ÓÀûÀÎ °³¹ß·Î Ä¡·á È¿°ú°¡ Çâ»óµÇ°í, ¼ö¼ú À§ÇèÀÌ °¨¼ÒÇϸç, ȸº¹ ½Ã°£ÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á ¹× ¿ø°ÝÁø·á ¼­ºñ½ºÀÇ ÀÌ¿ëÀÌ °¡´ÉÇØÁü¿¡ µû¶ó, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­´Â ½Å°æ¿Ü°ú Àü¹® Áö½Ä¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ Áõ°¡¿Í ½Å°æÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀçÁ¤ Áö¿øµµ »õ·Î¿î Ä¡·á Àü·«°ú Â÷¼¼´ë ÀÇ·á±â±â °³¹ßÀ» Áö¿øÇÏ¸ç ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç, ÀÇ·á±â¼ú ±â¾÷, ¿¬±¸±â°ü °£ÀÇ Çù·Â °ü°èÀÇ Áõ°¡´Â ³úô¼ö³¶Á¾ °ü¸®¸¦ À§ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ßÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¸ÂÃãÇü Ä¡·á °èȹ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÀÇÇÐÀÇ ¹ßÀü, ÁøÈ­ÇÏ´Â ÀÇ·á Á¤Ã¥, ȯÀÚ °á°ú °³¼±¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ³úô¼ö³¶Á¾ Ä¡·á ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(µÎ°³³» ÁöÁÖ¸·³¶Á¾, ô¼ö ÁöÁÖ¸·³¶Á¾), Áø´Ü(CT ½ºÄµ, MRI ½ºÄµ, Ãâ»ýÀü ÃÊÀ½ÆÄ °Ë»ç, ±âŸ Áø´Ü), Ä¡·á À¯Çü(³»½Ã°æ ³¶Á¾ õ°ø¼ú, õ°ø¼ú, ¿µ±¸ ¹è¾× ½Ã½ºÅÛ ¼ö¼ú), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Arachnoid Cysts Treatment Market to Reach US$1.7 Billion by 2030

The global market for Arachnoid Cysts Treatment estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Intracranial Arachnoid Cysts, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Spinal Arachnoid Cysts segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$363.2 Million While China is Forecast to Grow at 6.9% CAGR

The Arachnoid Cysts Treatment market in the U.S. is estimated at US$363.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$333.8 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Arachnoid Cysts Treatment Market - Key Trends & Drivers Summarized

What Are Arachnoid Cysts and How Are They Diagnosed?

Arachnoid cysts are fluid-filled sacs that develop between the brain or spinal cord and the arachnoid membrane, one of the three protective layers surrounding the central nervous system. These cysts are often congenital but can also arise due to trauma, infections, or complications from brain surgeries. While many arachnoid cysts remain asymptomatic and are discovered incidentally during imaging tests, symptomatic cases can lead to neurological complications, including headaches, dizziness, seizures, hydrocephalus, and cognitive impairment. Advances in diagnostic imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and cerebrospinal fluid flow studies have significantly improved the detection and characterization of arachnoid cysts. The increasing availability of high-resolution imaging tools has also enabled early diagnosis and treatment planning, reducing the risk of long-term complications. Furthermore, artificial intelligence (AI)-powered radiology solutions are enhancing the accuracy of cyst classification, allowing for better differentiation between symptomatic and incidental cysts. As healthcare providers continue to refine diagnostic protocols, the role of precision imaging in guiding treatment decisions is becoming increasingly critical in the management of arachnoid cysts.

How Are Surgical and Non-Surgical Approaches Evolving in Arachnoid Cyst Treatment?

The treatment of arachnoid cysts varies based on the severity of symptoms, cyst size, and location. While asymptomatic cysts often require no intervention, symptomatic cases may necessitate either non-surgical management or surgical procedures. Pharmacological treatments, including pain relievers, anti-seizure medications, and corticosteroids, are commonly used for symptom management in mild cases. However, for patients experiencing progressive neurological deficits, hydrocephalus, or increased intracranial pressure, surgical intervention is often required. Advances in neurosurgical techniques have revolutionized the treatment of arachnoid cysts, with minimally invasive procedures such as endoscopic fenestration, cystoperitoneal shunting, and microsurgical resection gaining prominence. Endoscopic fenestration, in particular, has emerged as a preferred approach due to its reduced risk of complications, shorter recovery times, and improved postoperative outcomes. Additionally, the integration of intraoperative neuro-navigation and real-time imaging has enhanced surgical precision, minimizing damage to surrounding brain structures. The growing adoption of robotic-assisted neurosurgery is further transforming treatment modalities, offering greater dexterity, reduced operative time, and enhanced patient safety. As surgical innovations continue to evolve, neurosurgeons are increasingly adopting personalized approaches to optimize outcomes for patients with arachnoid cysts.

What Market Trends Are Influencing the Demand for Arachnoid Cyst Treatments?

Several market trends are shaping the demand for arachnoid cyst treatments, including the rising incidence of neurological disorders, increasing investments in neurosurgical research, and advancements in precision medicine. The global prevalence of neurological conditions such as epilepsy, hydrocephalus, and traumatic brain injuries has heightened the focus on early intervention and advanced treatment strategies for arachnoid cysts. Additionally, the expansion of specialized neurology and neurosurgery centers has improved access to high-quality care, enabling more patients to benefit from cutting-edge treatment options. The growing emphasis on patient-centric healthcare is also driving demand for non-invasive and minimally invasive therapeutic approaches, prompting medical device manufacturers to develop innovative surgical instruments and neuro-navigation systems. Furthermore, the integration of AI and machine learning in neurosurgical planning is optimizing treatment outcomes by enabling predictive analytics and real-time decision-making. With increasing awareness of neurological health and advancements in medical technology, the landscape of arachnoid cyst treatment is rapidly evolving to meet the needs of patients and healthcare providers alike.

What Are the Key Growth Drivers Fueling the Arachnoid Cyst Treatment Market?

The growth in the arachnoid cyst treatment market is driven by several factors, including technological advancements in neurosurgical procedures, the rising adoption of AI-powered diagnostics, and increasing patient preference for minimally invasive treatments. The continuous development of endoscopic and robotic-assisted neurosurgery is enhancing treatment efficacy, reducing surgical risks, and improving recovery times. Additionally, the increasing availability of telemedicine and remote consultation services is expanding access to neurosurgical expertise, particularly in regions with limited healthcare infrastructure. The rising healthcare expenditure and government funding for neurological research are also fueling market expansion by supporting the development of novel treatment strategies and next-generation medical devices. Furthermore, growing collaborations between pharmaceutical companies, medical technology firms, and research institutions are accelerating the development of innovative therapies for arachnoid cyst management. As the demand for precision medicine and personalized treatment plans continues to rise, the arachnoid cyst treatment market is expected to experience sustained growth, driven by medical advancements, evolving healthcare policies, and the increasing focus on improving patient outcomes.

SCOPE OF STUDY:

The report analyzes the Arachnoid Cysts Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Intracranial Arachnoid Cysts, Spinal Arachnoid Cysts); Diagnosis (CT Scan, MRI Scan, Prenatal Ultrasound, Other Diagnosis); Treatment Type (Endoscopic Cysts Fenestration, Fenestration, Permanent Drainage System Surgery); End-Use (Hospital End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â